Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

  Sip Protocol

Masonic Cancer Research Center
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Back to Search Instructions

Protocol No. MT2006-13 Principal Investigator Weisdorf, Daniel
Phase Phase II
Age Group Both Scope Local
Title MT2006-13 Autologous Peripheral Blood Stem Cell Transplant for Acute Non-Lymphocytic Leukemia (ANLL)
Objective This clinical trial is studying how well an autologous stem cell transplant works in treating patients with acute myeloid leukemia.
Treatment Patients will receive chemotherapy, G-CSF, undergo bone marrow harvest or peripheral blood stem cell collection, total body irradiation (as applicable) and stem cell transplantation. After completion of study treatment, patients are followed periodically for 5 years.
Description Giving chemotherapy and colony-stimulating factors, such as G-CSF, may increase the number of stem cells in the blood for collection and freezing. Chemotherapy and radiation therapy are given to prepare for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and radiation.
Key Eligibility Patient must have a diagnosis of acute non-lymphoctyic leukemia (acute myeloid leukemia) and have achieved a 1st or 2nd bone marrow remission.
Applicable Disease Sites Acute myeloid leukemia (AML)
Hematologic Malignancies
Therapies Involved Blood and Marrow Transplant
Drugs Involved BUSULFAN (MYLERAN)
CYCLOPHOSPHAMIDE (CYTOXAN, NEOSAR)
DEXAMETHASONE (DECADRON)
ETOPOSIDE (VP-16)
FILGRASTIM (G-CSF, NEUPOGEN)
Status Open
Participating Institutions Masonic Cancer Center
Detailed Eligibility Patient must be no more than 70 years of age. Must be in remission during peripheral blood stem cell collection or marrow harvest. Patients must have adequate organ function. A signed informed consent and HIPAA authorization are required; an assent form is also required if patient is a minor.
Treatment Type Treatment
Contact Timothy Krepski Phone:612-273-2800
Email:tkrepsk1@fairview.org